Expression of total and phospho 4EBP1 in metastatic and non-metastatic renal cell carcinoma

被引:6
作者
Naito, Sei [1 ]
Ichiyanagi, Osamu [1 ]
Ito, Hiromi [1 ]
Kabasawa, Takanobu [2 ]
Kanno, Hidenori [1 ]
Narisawa, Takafumi [1 ]
Fukuhara, Hiroki [1 ]
Yagi, Mayu [1 ]
Kurota, Yuta [1 ]
Yamagishi, Atsushi [1 ]
Sakurai, Toshihiko [1 ]
Nishida, Hayato [1 ]
Kawazoe, Hisashi [1 ]
Yamanobe, Takuya [1 ]
Kato, Tomoyuki [1 ]
Makhov, Peter [3 ]
Kolenko, Vladimir M. [3 ]
Yamakawa, Mitsunori [2 ]
Tsuchiya, Norihiko [1 ]
机构
[1] Yamagata Univ, Fac Med, Dept Urol, 2-2-2 Iida Nishi, Yamagata, Yamagata 9909585, Japan
[2] Yamagata Univ, Fac Med, Dept Pathol Diagnost, Yamagata, Yamagata 9909585, Japan
[3] Fox Chase Canc Ctr, Canc Biol Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA
关键词
RCC; renal cell carcinoma; metastatic renal cell carcinoma; mRCC; kidney cancer; 4EBP1; phosphorylated; prognostic factor; recurrence free survival; overall survival; CANCER; PROGRESSION; PATHWAY; PROTEIN; TUMORS; EIF4E;
D O I
10.3892/ol.2019.10033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) is phosphorylated and activated by mammalian target of rapamycin complex 1, which serves as a regulator of cell growth, cell survival, metastasis and angiogenesis in many types of cancer. The aim of this study was to evaluate the role of phosphorylated 4EBP1 (p4EBP1) in primary renal cell carcinoma (RCC) as a biomarker in metastatic RCC (mRCC) and non-mRCC cohorts. Primary tumor tissue from 254 non-mRCC and 60 mRCC patients were immunohistochemically stained for t4EBP1 and p4EBP1. The disease-free interval (DFI) categorized by the expressions and clinical parameters were assessed by univariate and multivariate analysis in the non-mRCC cohort. Then, the cause-specific survival (CSS) was assessed in the mRCC cohort by the same methods as used in the non-mRCC cohort. In the non-mRCC cohort, patients with t4EBP1 expression had no RCC recurrence. Patients with p4EBP1 expression had the shorter DFI in univariate analysis (P=0.037). p4EBP1 and pT1b-4 expression levels were independent predictors for de novo metastasis. In the mRCC cohort, intermediate/poor MSKCC risk, non-clear cell RCC, and no p4EBP1 expression were correlated with poor CSS on multivariate analysis. Expression of p4EBP1 could be a predictive biomarker for de novo metastasis in non-mRCC patient cohort. By contrast, mRCC patients showing no p4EBP1 expression had shorter CSS than patients with p4EBP1 expression.
引用
收藏
页码:3910 / 3918
页数:9
相关论文
共 25 条
[1]   Treatment, Outcome and Prognostic Factors in Renal Cell Carcinoma - A Single Center Study (2000-2010) [J].
Achermann, Christof ;
Stenner, Frank ;
Rothschild, Sacha I. .
JOURNAL OF CANCER, 2016, 7 (08) :921-927
[2]   4E-Binding protein 1:: A key molecular "Funnel factor" in human cancer with clinical implications [J].
Armengol, Gemma ;
Rojo, Federico ;
Castellvi, Josep ;
Iglesias, Carmela ;
Cuatrecasas, Miriam ;
Pons, Berta ;
Baselga, Jose ;
Ramon y Cajal, Santiago .
CANCER RESEARCH, 2007, 67 (16) :7551-7555
[3]   Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib [J].
Beuselinck, Benoit ;
Vano, Yann-Alexandre ;
Oudard, Stephane ;
Wolter, Pascal ;
De Smet, Robert ;
Depoorter, Lore ;
Teghom, Corine ;
Karadimou, Alexandra ;
Zucman-Rossi, Jessica ;
Debruyne, Philip R. ;
Van Poppel, Hendrik ;
Joniau, Steven ;
Lerut, Evelyne ;
Strijbos, Michiel ;
Dumez, Herlinde ;
Paridaens, Robert ;
Van Calster, Ben ;
Schoffski, Patrick .
BJU INTERNATIONAL, 2014, 114 (01) :81-89
[4]   Tuning Specific Translation in Cancer Metastasis and Synaptic Memory: Control at the MNK-eIF4E Axis [J].
Bramham, Clive R. ;
Jensen, Kirk B. ;
Proud, Christopher G. .
TRENDS IN BIOCHEMICAL SCIENCES, 2016, 41 (10) :847-858
[5]  
Campbell L, 2015, AM J CANCER RES, V5, P2838
[6]   Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity [J].
Coleman, L. J. ;
Peter, M. B. ;
Teall, T. J. ;
Brannan, R. A. ;
Hanby, A. M. ;
Honarpisheh, H. ;
Shaaban, A. M. ;
Smith, L. ;
Speirs, V. ;
Verghese, E. T. ;
McElwaine, J. N. ;
Hughes, T. A. .
BRITISH JOURNAL OF CANCER, 2009, 100 (09) :1393-1399
[7]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[8]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386
[9]   Medical treatment of renal cancer: new horizons [J].
Greef, Basma ;
Eisen, Tim .
BRITISH JOURNAL OF CANCER, 2016, 115 (05) :505-516
[10]   pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner [J].
Guo, Jianping ;
Chakraborty, Abhishek A. ;
Liu, Pengda ;
Gan, Wenjian ;
Zheng, Xingnan ;
Inuzuka, Hiroyuki ;
Wang, Bin ;
Zhang, Jinfang ;
Zhang, Linli ;
Yuan, Min ;
Novak, Jesse ;
Cheng, Jin Q. ;
Toker, Alex ;
Signoretti, Sabina ;
Zhang, Qing ;
Asara, John M. ;
Kaelin, William G. ;
Wei, Wenyi .
SCIENCE, 2016, 353 (6302) :929-932